Skandinaviska Enskilda Banken Ab (Publ) Glaukos Corp Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$34.86 - $63.77 $26,911 - $49,230	772 Added 5.48%	14,865 $675,000
Q1 2022 May 11, 2022	SELL	$44.33 - $57.82 $302,507 - $394,563	-6,824 Reduced 32.62%	14,093 $815,000
Q2 2021 Aug 10, 2021	BUY	$73.06 - $97.7 $45,881 - $61,355	628 Added 3.1%	20,917 $1.77 Million
Q1 2021 May 14, 2021	SELL	$70.43 - $97.42 $120,787 - $167,075	-1,715 Reduced 7.79%	20,289 $1.7 Million
Q4 2020 Feb 11, 2021	BUY	$48.9 - $75.26 $30,122 - $46,360	616 Added 2.88%	22,004 $1.66 Million
Q3 2020 Nov 12, 2020	BUY	$37.23 - $50.97 $778,293 - $1.07 Million	20,905 Added 4328.16%	21,388 $1.06 Million
Q2 2020 Aug 13, 2020	BUY	$28.78 - $46.83 $13,900 - $22,618	483 New	483 $19,000

341

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.18B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.